References
- Ferlay J, et al. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5, Version 2.0. IARC Press, Lyon 2004
- Ziel H K, Finkle W D. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975; 293: 1167–1170
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 321–333
- Lethaby A, Suckling J, Barlow D, et al. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2004, CD 000402
- Anderson G L, Judd H L, Kaunitz A M, et al. The effects of progestogen plus progestin on gynaecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003; 290: 1739–1748
- Beral V, Bull D, Reeves G. Endometrial cancer and hormone replacement therapy in the Million Women Study. Lancet 2005; 365: 1543–1551
- Kloosterboer H J. Tibolone: a steroid with a tissue-specific action. J Steroid Biochem Molec Biol 2001; 76: 231–238
- Bruce D, Robinson J, Rymer J. Long-term effects of tibolone on the endometrium as assessed by bleeding episodes, transvaginal scan and endometrial biopsy. Climacteric 2004; 7: 261–266
- Archer D F, Hendrix S, Gallagher J C, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab 2007; 92: 991–998
- Langer R D, Landgren B-M, Rymer J, Helmond F A, OPAL investigators. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study. Am J Obstet Gynecol 2006; 195: 1320–1327
- Archer D F, Pickar J H. The assessment of bleeding patterns in postmenopausal women during continuous combined hormone replacement therapy: a review of methodology and recommendations for reporting of the data. Climacteric 2002; 5: 45–59
- Sturdee D W, Archer D F, Rakov V, Lang E. Low dose estradiol and norethindrone acetate: endometrial effects in postmenopausal women. Data presented at 11th IMS World Congress, Buenos Aires, October, 2005
- Hammar M, Christau S, Nathorst-Boos J, Rud T, Garre K. A double blind randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with symptoms. Br J Obstet Gynaecol 1998; 105: 904–911
- Panay N, Ylikorkala O, Archer D F, et al. Ultra-low dose estradiol and norethisterone acetate: effective menopause symptom relief. Climacteric 2007; 10: 120–131
- Pickar J H, Yeh I T, Wheeler J E, Cunnane M F, Speroff L. Endometrial effects of lower doses of conjugated equine oestrogens and medroxyprogesterone acetate: two-year substudy results. Fertil Steril 2003; 80: 1234–1240
- Lundström E, Bygdeson M, Svane G, Azavedo E, von Schoultz B. Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density. Climacteric 2007; 10: 249–256
- Johnson S R, Ettinger B, Macer J L, Ensrud K E, Quan J, Grady D. Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol. Obstet Gynecol 2005; 105: 779–787
- Riphagen F E. Intrauterine application of progestins in hormone replacement therapy. Climacteric 2000; 3: 199–211
- Hampton N R, Rees M C, Lowe D G, Rauramo I, Barlow D H, Guillebaud J. Levonorgestrel intra-uterine system (LNG-IUS) with conjugated equine estrogens: a successful regimen for HRT in perimenopausal women. Hum Reprod 2005; 20: 2653–2660
- Cicinelli E, de Ziegler D, Alfonso R, et al. Endometrial effects, bleeding control, and compliance with a new postmenopausal hormone therapy regimen based on transdermal estradiol gel and every-other-day vaginal progesterone in capsules: a 3-year pilot study. Fertil Steril 2005; 83: 1859–1863